Barry D. Quart - 29 Jun 2023 Form 4 Insider Report for Kiniksa Pharmaceuticals, Ltd. (KNSA)

Role
Director
Signature
/s/ Madelyn Zeylikman, Attorney-in-Fact
Issuer symbol
KNSA
Transactions as of
29 Jun 2023
Transactions value $
$0
Form type
4
Filing time
03 Jul 2023, 16:15:04 UTC
Previous filing
08 Jun 2023
Next filing
07 Jun 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KNSA Class A Common Share Options Exercise +5K 5K 29 Jun 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KNSA Restricted Share Units Options Exercise $0 -5K -100% $0.00* 0 29 Jun 2023 Class A Common Shares 5K Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer.
F2 The RSUs vested in a single installment on June 29, 2023; there was no expiration date for the RSUs.